TL;DR
Canada’s health regulatory agency has given a final positive recommendation for public reimbursement of Leqembi (lecanemab) for early Alzheimer’s. This decision could improve access to the drug nationwide, pending final administrative steps. The move reflects growing support for innovative Alzheimer’s treatments but details on implementation are still emerging.
Canada’s drug regulatory agency has issued a final positive recommendation in favor of publicly reimbursing Leqembi (lecanemab) for patients with early Alzheimer’s disease. This marks a significant step toward increasing patient access to the drug across the country, pending final administrative approval. The decision is based on evidence of the drug’s efficacy and safety in early-stage Alzheimer’s, and it signals a shift in Canadian health policy toward supporting innovative treatments for neurodegenerative conditions.
The Canadian Agency for Drugs and Technologies in Health (CADTH) announced on March 2026 that it has completed its review and recommends public reimbursement for Leqembi (lecanemab), a monoclonal antibody developed by Eisai and Biogen. The recommendation follows a thorough evaluation of clinical trial data indicating that Leqembi can slow cognitive decline in patients with early Alzheimer’s disease. The agency’s final report underscores the drug’s potential to address an unmet medical need and reduce long-term care costs associated with disease progression. While the recommendation is a key milestone, final approval for public funding will depend on subsequent decisions by provincial and territorial health authorities. The drug has already received regulatory approval from Health Canada in late 2025, making it available for prescribers and patients under certain conditions. The agency’s endorsement is expected to pave the way for broader access, although specific coverage details and eligibility criteria are still being finalized. The decision comes amid rising public and political interest in Alzheimer’s treatments, driven by increasing prevalence and limited existing options.Implications for Alzheimer’s Treatment Access in Canada
This recommendation could significantly improve access to Leqembi for thousands of Canadians diagnosed with early Alzheimer’s, a condition affecting over 400,000 individuals in the country. If implemented, it may lead to earlier intervention, potentially slowing disease progression and reducing long-term care costs. The move also signals a shift toward supporting innovative, high-cost therapies within Canada’s publicly funded healthcare system, aligning with global trends in neurodegenerative disease management. However, the actual impact will depend on final coverage decisions by provincial authorities, which may vary across regions. Healthcare providers and patient advocacy groups have welcomed the news, emphasizing the importance of accessible treatment options for early-stage Alzheimer’s, a stage where interventions are most effective.
Leqembi (Lecanemab) for early Alzheimer’s treatment
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background on Leqembi and Canadian Alzheimer’s Policy
Leqembi (lecanemab) was approved by Health Canada in late 2025 after clinical trials demonstrated its ability to slow cognitive decline in patients with early Alzheimer’s disease. The drug, developed by Eisai and Biogen, is one of the first disease-modifying therapies targeting amyloid plaques in the brain. Prior to this, Canada’s coverage of Alzheimer’s treatments has been limited, with most therapies focusing on symptomatic relief rather than slowing disease progression. The decision by CADTH to recommend public reimbursement marks a notable policy shift, reflecting increased willingness to fund innovative, high-cost treatments for neurodegenerative diseases. Historically, Canadian drug reimbursement decisions have balanced clinical benefit against cost-effectiveness, often leading to delays in coverage for new therapies. The current development follows a period of heightened public and political pressure to improve access to Alzheimer’s treatments, amid rising prevalence and aging demographics.
Next Steps for Final Approval and Coverage Details
While the recommendation is a critical step, it is not yet clear when and how provincial health authorities will implement coverage for Leqembi. Details on patient eligibility, cost-sharing, and distribution are still being finalized. Additionally, it remains uncertain whether all provinces will adopt the recommendation uniformly or if some will impose additional restrictions. The timeline for the final administrative approval process and actual patient access remains to be confirmed. Experts caution that the transition from recommendation to actual coverage can involve delays, especially given the high costs associated with the drug and the complexities of provincial healthcare funding.
Final Administrative Decisions and Implementation Timeline
The next step involves provincial and territorial health authorities reviewing the CADTH recommendation and making final coverage decisions. This process could take several weeks to months, depending on regional priorities and budget considerations. Once approved, healthcare providers will be able to prescribe Leqembi under publicly funded programs, and patients will gain access through specialized clinics. Advocacy groups are urging swift action to minimize delays, emphasizing the importance of early intervention for Alzheimer’s. Meanwhile, ongoing monitoring of the drug’s real-world effectiveness and safety will inform future policy adjustments. The government and health agencies are expected to release detailed guidelines and eligibility criteria in the coming weeks.
Key Questions
What does the final positive recommendation mean for patients with early Alzheimer’s in Canada?
It indicates that Leqembi is now recommended for public reimbursement, which could make it more accessible to eligible patients across Canada once provincial approvals are in place.
When will patients be able to start accessing Leqembi through public healthcare?
Final coverage decisions are still pending at the provincial level, and the timeline for implementation is uncertain. It could take several weeks to months after provincial approval.
Are there any restrictions on who can receive Leqembi?
Details on eligibility criteria are still being developed. Typically, access will be limited to patients with early-stage Alzheimer’s confirmed by diagnostic criteria.
How might this decision impact Alzheimer’s care in Canada overall?
If fully implemented, it could lead to earlier treatment, slow disease progression, and reduce long-term care costs, representing a significant shift in Alzheimer’s management.
What are the main uncertainties remaining?
The key uncertainties include the final timing of provincial coverage, specific eligibility criteria, and how the drug will be integrated into existing healthcare services.
Source: primary
